Data show clinical benefit from mitral valve clip device

Sep 21, 2010

A percutaneous mitral valve clip designed to stop mitral valve regurgitation demonstrated clinical benefit as measured by the degree of mitral regurgitation, according to a study presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. Mitral valve regurgitation is one of the most common forms of heart disease.

The study was led by James Hermiller, MD, Director of Cardiovascular Intervention at the St. Vincent Heart Center of Indiana (Indianapolis, IN.)

"Significant measures of clinical benefit are observed one year following successful therapy," said Dr. Hermiller.

The study, EVEREST II, is a prospective, multi-center, randomized designed to compare the safety and effectiveness of the MitraClip System with in the treatment of mitral regurgitation (MR). Measures of 12-month clinical benefit, defined as improvements in left ventricular (LV) function and symptomatic improvement, were evaluated for the Device Group and Control Group, and have been previously reported. However, observed clinical benefit by 12 month MR grade has not been reported.

Significant improvement in LV function, NYHA Functional Class, and Quality of Life scores was observed for all device patients with ongoing success (MR≤2+ at 12 months). Patients with MR reduced to 1+, 1+ to 2+, or 2+ at 12 months demonstrated marked clinical benefit, with significant improvements noted from baseline to 12 months.

A detailed analysis of these data will be presented during The 'Best of the Best' TCT 2010 Abstracts Session on Friday, September 24 in the Main Arena at the Washington Convention Center.

Explore further: Using feminist theory to understand male rape

Provided by Cardiovascular Research Foundation

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Open chest surgery alternative found

Nov 20, 2006

A U.S. scientist has found an alternative to open chest surgery in treating mitral regurgitation -- blood leaking into the heart through the mitral valve.

Mount Sinai performs first tricuspid ring implantation

Sep 13, 2010

David H. Adams, MD, Marie-Josée and Henry R. Kravis Professor and Chairman of the Department of Cardiothoracic Surgery at The Mount Sinai Medical Center, has performed the first implantation of the Medtronic Tri-Ad ...

Recommended for you

Using feminist theory to understand male rape

3 hours ago

Decades of feminist research have framed rape and sexual assault as a 'women's issue', leaving little room for the experiences of male victims. But a new study published in the Journal of Gender Studies suggests that feminist ...

Simulation-based training improves endoscopy execution

Oct 18, 2014

(HealthDay)—Simulation-based training (SBT) improves clinicians' performance of gastrointestinal endoscopy in both test settings and clinical practice, according to research published in the October issue ...

Data sharing in pharmaceutical industry shows progress

Oct 16, 2014

To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies. Brian L. Strom, chancellor of Rutgers Biomedical and Health ...

Swiss drug maker Roche posts flat 3Q sales

Oct 16, 2014

(AP)—Swiss drugmaker Roche Holding AG has reported "stable" or flat sales for the first nine months of 2013 but says the results show strong demand for its cancer drugs and emerging new products.

User comments : 0